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Abstract
Although less clinical intervention studies have been performed with fibrates than with statins,
there are evidences indicating that fibrates may reduce risk of cardiovascular events. The potential
clinical benefit of the fenofibrate will be specified by the ongoing Fenofibrate Intervention and Event
Lowering in Diabetes (FIELD) study, which rationale, methods and aims have been just published.
Controlled clinical trials show similar or even greater cardiovascular benefits from statins-based
therapy in patient subgroups with diabetes compared with overall study populations. Therefore,
statins are the drug of first choice for aggressive lipid lowering actions and reducing risk of coronary
artery disease in these patients. However, current therapeutic use of statins as monotherapy is still
leaving many patients with mixed atherogenic dyslipidemia at high risk for coronary events. A
combination statin/fibrate therapy may be often necessary to control all lipid abnormalities in
patients with metabolic syndrome and diabetes adequately, since fibrates provide additional
important benefits, particularly on triglyceride and HDL-cholesterol levels. Thus, this combined
therapy concentrates on all the components of the mixed dyslipidemia that often occurs in persons
with diabetes or metabolic syndrome, and may be expected to reduce cardiovascular morbidity and
mortality.
Safety concerns about some fibrates such as gemfibrozil may lead to exaggerate precautions
regarding fibrate administration and therefore diminish the use of the seagents. However, other
fibrates, such as bezafibrate and fenofibrate appear to be safer and better tolerated. We believe
that a proper co-administration of statins and fibrates, selected on basis of their safety, could be
more effective in achieving a comprehensive lipid control as compared with monotherapy.
Due to their beneficial effects on glucose and lipid metab-
olism, peroxisome proliferator activated receptors
(PPAR's) alpha agonists (fibrates) are good potential can-
didates for reducing the risk of myocardial infarction (MI)
in subjects with metabolic syndrome [1-3]. Although less
clinical intervention studies have been performed with
fibrates than with statins, there are evidences indicating
that fibrates may reduce risk of cardiovascular disease and
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particularly non-fatal MI [4-10]. Interestingly, reduction
of cardiovascular disease with one of the fibric acid deri-
vates – gemfibrozil – was more pronounced in patients
displaying baseline characteristics very similar to meta-
bolic syndrome definitions [4,5].
There have been no direct head-to-head comparisons of a
statin with a fibrate in any clinical endpoint trial. How-
ever, compared with statins, fibrates appear to more selec-
tively target the therapeutic goals in obese individuals
with features of insulin resistance and metabolic syn-
drome (i.e. with near-goal low-density lipoprotein (LDL)-
cholesterol and inappropriate high-density lipoprotein
(HDL)-cholesterol and triglyceride levels).
The primary-prevention trial Helsinki Heart Study
showed that treatment with gemfibrozil led to a signifi-
cant reduction in major cardiovascular events [4]. Regard-
ing secondary prevention, in the VAHIT study (Veterans
Affairs High-density lipoprotein cholesterol Intervention
Trial) – which included 30% of diabetic patients – gemfi-
brozil reduced the occurrence of major cardiovascular
events by 22 % [5]. Similarly, reduction of cardiovascular
disease with gemfribrozil was more pronounced in
patients displaying above three of the features of meta-
bolic syndrome [11,12].
In two previous small studies bezafibrate decreased the
rate of progression of coronary atherosclerosis and
decreased coronary event rate [6,7]. In another large trial
in 1568 men with lower extremity arterial disease with a
relatively short follow-up period, bezafibrate reduced the
severity of intermittent claudication for up to three years.
[8]. Ingeneral, the incidence of coronary heart disease in
patients on bezafibrate has tended to be lower , but this
tendency did not reach statistical significance. However,
bezafibrate had significantly reduced the incidence of
non-fatal coronary events, particularly in those aged <65
years at entry, in whom all coronary events may also be
reduced [8]. In the Bezafibrate Infarction Prevention (BIP)
study an overall trend of a 9.4% reduction of the inci-
dence of primary end point (fatal or non-fatal myocardial
infarction or sudden death) was observed. The reduction
in the primary end point in 459 patients with high base-
line triglycerides (≥200 mg/dL) was significant [9]. These
results are consistent with studies in experimental models
showing that pre-treatment of rats with the PPAR-alpha
agonist clofibrate causes a significant reduction in
induced myocardial infarct size of 43% [13].
Recently, reduced incidence of type 2 diabetes in patients
with impaired fasting glucose level on bezafibrate has
been demonstrated [14]. The potential clinical benefit of
the other widespread fibric acid derivative, fenofibrate, on
the reduction of cardiovascular disease is still unknown
and will be specified by the ongoing Fenofibrate Interven-
tion and Event Lowering in Diabetes (FIELD) study,
which rationale, methods and aims have been just pub-
lished [15]. It will be the largest (approximately 10000
patients) ever conducted fibrate-based controlled clinical
trial in diabetic patients. The results are expected for 2005.
An added strength of this trial is its ability to examine
important clinical outcomes across diverse ethnic and
gender subgroups. The results of this study will clarify
whether the beneficial lipid-modifying effects of micro-
nised fenofibrate lead to a reduction of cardiovascular
morbidity and mortality.
Despite increasing use of statins, a significant number of
coronary events still occur and many of such events take
place in patients presenting with the metabolic syndrome.
Whereas statins remain the drug of choice for patients
who need to achieve the LDL-cholesterol goal, fibrate
therapy may represent the alternative intervention for
subjects with atherogenic dyslipidemia typical for meta-
bolic syndrome and an LDL-cholesterol already close to
goal values. In addition, the concomitant use of fibrates
seems to be attractive in patients whose LDL-cholesterol is
controlled by statin therapy but whose HDL-cholesterol
and/or triglyceride levels are still inappropriate [16-19].
This strategy will be tested in the ongoing Action to Con-
trol Cardiovascular Risk in Diabetes (ACCORD) trial [20].
The factor that dominates in overweight-related metabolic
syndrome is the permanent elevation of plasma free fatty
acids (FFA) and the predominant utilization of lipids by
the muscle inducing a diminution of glucose uptake and
insulin resistance. Currently, an insulin-resistant state – as
the key phase of metabolic syndrome – constitutes the
major risk factor for development of macrovascular com-
plications [21-23]. On the basis of the current concept of
the evolution of adipogenesis via PPAR modulation
toward insulin resistance and atherothrombotic macrov-
ascular complications (including MI), the decreasing of
plasma FFA and improving of insulin sensitization by
PPAR agonists seems to be a logical and valuable goal for
therapy.
It is important to note that on a whole-body level, lipid
and glucose metabolisms interact intimately. Briefly,
PPAR alpha is activated by fibric acids (e.g. bezafibrate)
and form heterodimers with the 9-cis retinoic acid recep-
tor (RXR). These heterodimers bind to peroxisome prolif-
erator response elements, which are located in numerous
gene promoters and increase the level of the expression of
mRNAs encoded by PPAR alpha target genes. Bezafibrate
reduces triglyceride plasma levels through increases in the
expression of genes involved in fatty acid-beta oxidation
and by decrease in apolipoprotein C-III gene expression.
Fibric acids increase HDL-cholesterol partly by increasingCardiovascular Diabetology 2004, 3:10 http://www.cardiab.com/content/3/1/10
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apolipoprotein A-I and apolipoprotein A-II gene expres-
sion. Their triglyceride-lowering and HDL-cholesterol
raising effects lead to decreased systemic availability of
fatty acid, diminished fatty acid uptake by muscle with
improvement of insulin sensitization and reduced plasma
glucose level [24-28].
Evidence also suggests that there is a 'fibrate effect' that
mediates the reduction in CHD risk beyond the favorable
impact of these agents on HDL-cholesterol levels. This last
notion is consistent with the pleiotropic effects of fibrates
which are known to be related to their mechanisms of
action [29]. Being PPAR alpha ligands, fibrates have a sig-
nificant impact on the synthesis of several apolipopro-
teins (apo) and enzymes of lipoprotein metabolism as
well as on the expression of several genes involved in fibri-
nolysis and inflammation. Such changes contribute to
improve the catabolism of triglyceride-rich lipoproteins,
leading to a substantial increase in HDL-cholesterol levels
accompanied by a shift in the size and density of LDL par-
ticles (from small, dense LDL particles to larger, more
buoyant cholesteryl ester-rich LDL).
Controlled clinical trials show similar or even greater car-
diovascular benefits from statins-based therapy in patient
subgroups with diabetes, impaired fasting glucose, and
metabolic syndrome, compared with overall study popu-
lations. Therefore, statins are the drug of first choice for
aggressive lipid lowering actions and reducing risk of cor-
onary artery disease in these patients. However, current
therapeutic use of statins as monotherapy is still leaving
many patients with mixed atherogenic dyslipidemia at
high risk for coronary events.
A combination statin/fibrate therapy may be often neces-
sary to control all lipid abnormalities in patients with
metabolic syndrome and diabetes adequately, since
fibrates provide additional important benefits, particu-
larly on triglyceride and HDL-C levels. Thus, this com-
bined therapy concentrates on all the components of the
mixed dyslipidemia that often occurs in persons with dia-
betes or metabolic syndrome, and may be expected to
reduce cardiovascular morbidity and mortality.
Safety concerns about some fibrates such as gemfibrozil
may lead to exaggerate precautions regarding fibrate
administration and therefore diminish the use of the sea-
gents. However, other fibrates such as bezafibrate and
fenofibrate appear to be safer and better tolerated [30-36].
We believe that a proper co-administration of statins and
fibrates, selected on basis of their safety, could be more
effective in achieving a comprehensive lipid control as
compared with monotherapy.
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